#### In this edition...

While a number of biotech stocks are doomed to be investment failures, others, especially those building businesses in the biologics (proteins and peptides) space appear to be almost guaranteed investment winners. The proviso is that they have a platform technology or similar assets locked away with good IP. Another international acquisition this week looks to have increased demand for biologics companies yet again.

We also initiate coverage on tissue engineering in company bioMD and introduce readers to a private company and potential IPO play in 2008, TGR Biosciences.

#### The editors

Companies covered: BOD, PTD, PYC, TGR Biosciences

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.0%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.3%
Year 7 (from 4 May '07)	-8.6%
Cumulative Gain	198%
Av Annual Gain (6 yrs)	26.8%

*Bioshares* is published by Blake Industry & Market Analysis Pty Ltd. The company also provides market and company analysis of the Australian pharmaceutical and biotech industries for local and international funds management institutions, venture capital funds and other related industry groups. For further details contact David Blake (see details below).

Blake Industry & Market Analysis Pty Ltd ACN 085 334 292 PO Box 193 Richmond Vic 3121 AFS Licence No. 258032

Enquiries for *Bioshares* Ph: (03) 9326 5382 Fax: (03) 9671 3633 Email: info@bioshares.com.au **David Blake** Ph: (03) 9326 5382 Email: blake@bioshares.com.au **Mark Pachacz** Ph: (03) 9671 3222 Email: pachacz@bioshares.com.au

Individual Subscriptions (48 issues/year) \$320 (Inc.GST) Edition Number 234 (28 September 2007) ISSN 1443-850X

Copyright 2007 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED. Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

# Bioshares

28 September 2007 Edition 234

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies.

## BMS Acquires Adnexus; Demand for Biologics Companies Remains Strong

External events continue to play an important role in shaping the destiny of several Australian biotech companies, including Peptech (PTD: \$1.24) and Phylogica (PYC: \$0.28).

This week, **Bristol Myers Squibb** announced its intention to buy the US-based **Adnexus**, a privately-held biologics company for a net price of US\$415 million. Adnexus is not an antibody company, but has been using a design engine to develop targeted drugs based on fragments of the common structural protein fibronectin.

#### 5-fold return

Owners of Adnexus stand to gain up to US\$75 million if certain development and regulatory milestones are met. Since it was founded in 2002, Adnexus has received around \$76 million in funding, mainly from venture capital investors, who own about 85% of the company. Adnexus' investors look set to achieve in the vicinity of a 5-fold return on their investment. This is not dissimilar to the return **Peptech** made on its investment in **Domantis**, which was acquired late in 2006 by **GlaxoSmithKline** for US\$453 million.

The parallels between Adnexus and Domantis are striking. Both had been developing a technology platform to generate small protein fragments that are a tenth to a fifteenth the size of an IgG antibody. Both offered a fresh patent position that could overcome incumbent antibody binding and antibody engineering patent estates. Both offered a class of compound that could potentially be more flexible in dosing and administration, and possibly cheaper to manufacture, but neither had validated their technology in proof-of-concept human trials.

Domantis (originally Diversys) was founded in 2000, whereas Adnexus was originally founded as **Compound Therapeutics** in 2002. However, Adnexus did acquire **Phylos**, the original creator of the core protein display technology called **PROfusion**, in 2004. Phylos was founded in 1997.

#### A steady flow of M&A

There has been steady flow of M&A in the global biologics space, with the Peptech merger with Evogenix one the of most recent. Another major acquisition for 2007 was Eisai's acquisition of the US-based privately held Morphotek in March for US\$325 million, net of cash. These transactions follow on from AstraZeneca's purchase of Cambridge Antibody Technologies (US\$1.3 billion), Merck's purchase of Abmaxis (US\$80 million) and GlycoFi (US\$400 million) in 2006. And the early September announcement of a collaboration between Boehringer Ingelheim and Ablynx, covering its antibody-derived proteins, which also included an equity investment, may set the scene for another acquisition in the next year or so.

The ongoing demand for biologics companies with either novel proprietary platform technologies and/or novel protein engineering skills and/or protein drug development skills means that Peptech and Phylogica stand a very strong chance of being acquired by larger pharmaceutical firms in the medium term. Phylogica is similar to Adnexus in that it has a powerful dis-

Cont'd on page 5

### BioMD Approaches Clinic with its ADAPT Tissue Engineering Technology

BioMD (BOD: 14 cents) listed on the ASX in 2004 to commercialise its safety syringe technologies (the POP safety injection needle and the prefilled safety syringe). The priority for the company now is the commercialisation of its tissue engineering technology. BioMD is seeking to license the prefilled safety syringe prototype to syringe manufacturers.

In November 2005, bioMD acquired its initial interest in a tissue engineering technology company, **Celxcel Pty Ltd**, which has developed the ADAPT tissue processing technology. The technology is due to be tested in clinical trials in South Africa for the repair of cardiac tissue repair. Biological tissue implants are generally accessed from bovine or porcine sources. However, the harsh chemical treatment to render the implanted tissue immunologically inactive results in reduced lifespan of the tissue. bioMD is seeking to extend the life span if implanted tissue with its ADAPT technology.

bioMD has increased its ownership of Celxcel to 76%. Over the last 12 months the company has delivered a number of positive preclinical data supporting its tissue engineering technology, culminating in the presentation of its results at a major heart valve disease conference earlier this year.

#### History of the ADAPT technology

One of the pioneers of the ADAPT tissue engineering technology is Celxcel's Chief Scientific Officer, Dr Leon Neethling. Neethling had worked on tissue engineering technologies in South Africa for approximately 10 years before moving to Australia to continue his work. Between 2000-2005 the final product development on the ADAPT process technology was completed with Celxcel being formed in 2001.

The standard process for treating implantable tissue from animal sources has involved the use of the chemical glutaraldehyde that allows crosslinking (stabilisation) of the tissue matrix. DNA is removed from the tissue prevent any immune responses and the end result is a neutral collagen matrix that can facilitate rejuvenated tissue repair.

However, the problems with using large volumes of glutaraldehyde are its cytotoxic properties and the increased level and rate of calcification of the implanted tissue that reduces the elasticity and lifespan of the tissue.

The ADAPT tissue treatment process reduces the amount of glutaraldehyde used by around 90% and preclinical results have shown the not only does the process reduce calcification (and hence stiffening) of the tissue, but provides suitable environment within the collagen matrix that allows tissue rejuvenation, including the migration of fibroblasts and even capillary formation in transplanted tissue.

Results from preclinical studies Study I

Over the last year, BioMD (Celxcel) has generated several positive

preclinical data using the ADAPT process. In March, the company reported data from a preclinical study in 45 young rats (15 in each group), where a bovine pericardial (the tissue cavity that surrounds the heart) was treated with the ADAPT process and compared with the two commercially available bovine pericardial tissue patches. The patches were implanted subcutaneously for 200 days.

The results showed that two commercially available patches became densely fibrotic after 200 days with one showing only limited fibroblast infiltration into the patch and the second patch degenerated showing signs of inflammation.

In contrast, the ADAPT treated patches were free from any dense fibrotic tissue and showed signs of capillary formation with red blood cells circulating in the patches. There was also formation of

Cont'd over

#### **Biological versus Mechanical Heart Valves**

Mechanical and biological heart valves were first developed in the 1960s. Mechanical heart valves generate global sales in the order of US\$1 billion a year. While these types of valves have been more popular in the past, making up as much as 80% of the total valve replacement market, today biological heart valve implants from pigs, cows or donated human valves such as the one received by Opposition Leader Kevin Rudd, are approaching 60% market share and growing at 11% compared to the near stagnant growth of mechanical valves. BioMD is targeting the treatment of porcine and bovine heart valves. Over 170,000 valve replacement procedures are conducted worldwide every year.

Whilst mechanical valves should last the life of the patient and biological valves last only 10 -15 years, there are downsides to the mechanical valves. These include the requirement to receive continued anticoagulant therapy with regular monitoring of blood properties; the audible noise of the mechanical device; and the risk of excessive bleeding from a major injury.



Opposition Leader Kevin Rudd: Recipient of a donated human heart valve

fat tissue within these patches which was also a positive sign of tissue rejuvenation. Some of the rats within this study were followed for a full 12 months where the positive remodelling properties in the ADAPT treated tissue were maintained.

#### Study II

In this trial, 14 implants of ADAPT treated kangaroo pericardial tissue and ADAPT treated bovine pericardial tissue were implanted into sheep, into the jugular vein to form a vascular roof. The aim was to investigate the possible use of these tissue implants for possible use in heart valve leaflets.

The results were very successful, showing no calcification after 200 days and the presence of fibroblast cells with evidence of endothelial cell and capillary formation.

In the same trial, positive results were also obtained in three implants of ADAPT treated kangaroo carotid artery grafts indicating the potential to use this tissue and process in heart bypass surgery. Kangaroo tissue has appealing qualities because of the animals have almost no cholesterol, where in comparison pigs have a high cholesterol level.

#### Forthcoming clinical trial

These positive preclinical results have paved the way for a 50 person clinical trial to be conducted at the Universitas Hospital in Bloemfontein, South Africa. Unconditional ethics approval from the hospital has been received. The trial is anticipated to start early next year. It should take about six months to recruit the patients and the patients will be followed for 12 months after the procedure. Final results can be expected by the end of 2009 if the trial runs to schedule.

The patients to be recruited will be young adults who have a congenital heart defect, being either a hole in an internal wall of the heart or to reconstruct deformities in the aorta. The patients will receive an ADAPT treated bovine patch. Bovine pericardial tissue is used because it is the right thickness (about 0.7mm) and also is consistent in thickness. South Africa has been selected because of the high rate of congenital heart defects. Celxcel's CSO, Leon Neethling also has strong ties to the teaching hospital where the trial is to be conducted, having previously worked at the university and maintains a position as a visiting professor to the university. He is employed by the company for four days a week at the University of Western Australia. Commencement and completion of the trial will be major milestones for the company.

The implant material will be sourced from local (WA) bovine pericardial tissue. It will be treated at a third party GMP manufacturing facility although that site has yet to be confirmed.

#### Applications of the technology

The company is looking to develop the ADAPT technology for five distinct areas of use. Its aim is to outlicense the process to different commercial parties. The five commercial applications selected are:

• Cardiovascular repair, which is to be investigated in the forthcoming clinical trial

- Treatment of biological heart valves
- Repair of the abdominal wall, such as repairs to the pelvic floor or hernia
- Orthopedics, for repair of ligaments or rotator cuffs in joints
- Plastic surgery, as a dermal filler that will regenerate into living host tissue or for use in mastectomy reconstruction

Over the next 12 months, the objective is to secure at least one and potentially two licensing deals.

#### Risks

#### Patents

BioMD's patent position over its subsidiary's ADAPT technology has not been secured in major regions. A patent has been granted in Australia and an international patent application has been lodged. However, the ADAPT tissue treatment process is one of five processes that makes up the technology and some of the other processes will be maintained as trade secrets.

#### Copycats

The company's commercial model is to outlicense the technology to different parties for separate uses. However, being a processing technology, it may be difficult to ensure this technology is used by only licensed parties.

#### Funding

At June 30, the company had cash assets of \$2.1 million. The company's loss for the previous year was also \$2.1 million. With clinical trials due to begin in coming months, bioMD will likely need to raise further funds in this time.

#### Competition

There are competing process technologies that can reduce calcification in implanted tissue. BioMD will need to prove its process results in material that is superior to current available treated material. Preclinical results to date support the development of the ADAPT technology.

#### Summary

BioMD through its investment in tissue engineering company Celxcel is moving towards major milestones in clinical trials in coming months. The last 12 months has generated very positive preclinical data that supports the decision to progress to the clinical phase of development. The market for biological implant patches is valued in excess of \$1 billion a year and the growing popularity of biological heart valves is certain to sustain interest in improvements that can emanate from tissue processing technologies.

The company is current capitalised at \$12 million

#### Bioshares recommendation: Speculative Buy Class B

Bioshares

# Private Company Profile – TGR Biosciences Pty Ltd

On occasion *Bioshares* reports on private companies that have indicated that at some stage they will seek a listing on the ASX, if not some other exchange. One company in this category is **TGR Biosciences**, which is based in Adelaide.

TGR Biosciences has flagged its intention to seek an IPO in mid-2008. However, such an action is contingent on the company successfully achieving several milestones and also securing funding through a pre-IPO round by December, 2007. A list of other potential IPOs can be found on the next page.

TGR Biosciences was founded in 2001 as a spin-out from the **CRC** for Tissue Growth and Repair. The firm employs 20 people.

Revenues for FY2007 were \$2.5 million, level with the previous year's figure. Product and service income for FY 2006 was \$1.5 million, up from \$1 million in FY2005. Product and service income for FY 2007 has not been disclosed.

#### The TGR Biosciences Business

TGR Biosciences has two business units, one encompassing therapeutic product development, the other focused on the manufacture and sales of proprietary cell-based screening assays, marketed as the 'SureFire' assay kits and distributed by partner **Perkin Elmer.** 

#### Products under development

#### Therapeutics

The company's lead therapeutic product candidate is Lactermin, a medical food treatment for oral mucositis (mouth ulcers), a side effect from chemo- and radio-therapy. Lactermin is a growth factor

derived from milk and is currently in a Phase II trial. Recruitment is currently 50% complete. The company is also studying wound healing and dermal regeneration product possibilities.

#### 'Surefire' Assay Kits

The company has now brought 14 'Surefire' assay kits to market and has secured a contract with a pharmaceutical company for the development of a further 20 kits.

#### **Funding History and Outlook**

TGR Biosciences has raised an estimated \$9 million since its inception in 2002. The company has also been successful in obtaining government grants, including a \$1.35 million Commercial Ready grant in the June quarter of 2006. TGR Biosciences is looking to raise approximately \$5 million in a pre-IPO funding round.

#### **Board and management**

The MD and CEO of TGR Bioscience is Leanna Reed, with other board members being Bob Moses (Chair), John Bastian and Mike Hirshorn (Kestrel Capital).

#### Summary

TGR Biosciences is a well managed company with clear focus and it is supported by a solid board. The company has built a track record as an effective communicator. Should the company's lead product Lactermin obtain trial results sufficient to support marketing activities, then a worthwhile investment opportunity may became available through an IPO.

**Bioshares** 

Company	Price (current)	Price (current) Price added to	
		portfolio	
Acrux	\$1.38	\$0.83	
Alchemia	\$0.83	\$0.67	
Biota Holdings	\$1.67	\$1.55	
Circadian Technologies	\$1.23	\$1.45	
Clinuvel Pharmaceuticals	\$0.45	\$0.66	
Cytopia	\$0.55	\$0.46	
Chemgenex Pharma.	\$1.05	\$0.38	
Optiscan Imaging	\$0.40	\$0.35	
Peplin	\$0.86	\$0.83	
Peptech	\$1.24	\$1.31	
Pharmaxis	\$4.05	\$3.15	
Phylogica	\$0.28	\$0.42	
Probiotec	\$1.20	\$1.12	
Progen Pharmaceuticals	\$3.39	\$3.52	
Sirtex Medical	\$3.95	\$3.90	
Starpharma Holdings	\$0.32	\$0.37	
Sunshine Heart	\$0.18	\$0.19	
Tissue Therapies	\$0.49	\$0.58	
Universal Biosensors	\$1.28	\$1.23	



	<ul> <li>Biologics Transactions', from page 1</li> </ul>
Pool of potential biotech floats(in the next 12 months)(revised and updated from Bioshares 192 - 10 Nov. 2006)Possible IPOsHatchtechImmune System Therapeutics(formerly Pacmab)- likelyContinence Control SystemsMimeticaGenera Biosystems- likelyCleveland BiosensorsTGR Biosciences- flagged mid - 08Opal TherapeuticsEcobioticsCNS BioCryptopharmaKaybanVegenics- strong possibilitySienna Diagnostics- flagged O1 08	<ul> <li>covery engine with which to generate novel scaffolds. Peptech is a currently running the first clinical trial of a domain antibody compound (PN0621), but also possesses antibody humanisation and optimisation technologies. Triggers for such moves might include the generation of data from human clinical trials or highly validated preclinical studies.</li> <li>Peptech is capitalised at \$290 million, and retains an estimated \$165 million in cash resources. Phylogica is capitalised at \$40 million, with an estimated \$7.5 million in cash assets.</li> <li>Bioshares recommendations:</li> <li>Peptech – Speculative Buy Class A</li> <li>Phylogica – Speculative Buy Class A</li> <li>Bioshares recommendations and class A</li> </ul>
Sleep Diagnostics – possible, 08 Mems-ID Underway/pending Impedimed Actinogen Oncaida	

# Bioshares

Subscribe to Bioshares and have a look at the depth of coverage that comes your way in a twelve month subscription period.

A subscription to Bioshares for the year ending June 30, 2007 provided the following:

- 4 Quarterly Sector Reviews
- 4 Quarterly Cash Flow Statement reviews
- Annual Analysis of Stockbroker Performance
  - Annual CEO Salary Survey
  - Annual Clinical Trials Survey
- 4 IPO Profiles (QRxPharma, Stem Cell Sciences, Patrys, Universal Biosensors)

A Survey of Australian Biotech CEOs Regarding M&A (Devine et al)

- Features on Tier-1 companies, M&A trends and, pain drug and antibody drug development
  - business trends

...plus more than 100 specific in-depth analysis and updates on ASX listed biotech stocks

\$320 per 48 issues (less than \$7 per issue) – subscription details are on the back page

We bioshares Rates Stocks         in purpose of valuation, <i>Busicinous</i> divides biostes hords into hords, bioste transpositive cash (boxs, biscoy of boses, or at early set) of the second group, which are second group are set to set the second group are set to set the second group. Set the second group are set to set the second group are set to set the second group, which are second group, which are second group, which are second group. Set the second group, which are second group, which are second group. Set the second group are set to set the second group, which are second group. Set the second group are set to set the second group, which are second group. Set the second group are set to set the second group are set to set the second group. Set the second group are set to set to set the second group are set to set to set the second group. Set the second group are set to set to set the second group. Set the second group are set to set to set to set to set the second group. Set the second group are set to set	snares	Number 234 – 28 September 2007	Page 6
<pre>state unique of valuation. BiosNarre divides biotech stocks into valuations. BiosNarre divides biotech stocks into value or valuation groups exists with existing positive stocks how to relative cash flows. This second group, within a sessen- tis within these stocks.</pre>	ow Biosha	ares Rates Stocks	Group B
<pre>crategores. The ind group are shocks will existing positive cash items foot producing positive cash draws, history of losses, or at early go commercialization. In this second group which are stored is early and are positive cash draws, history of losses, or at early is existing positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early is early and are positive cash draws, history of losses, or at early and the early of the e</pre>	r the purpos	e of valuation, <i>Bioshares</i> divides biotech stocks into	Stocks without near term positive cash flows, history of losses, or at
hand mater term positive cash flows, listing of loses, or at early spectrative propositions. <i>History of loses</i> , or at early is of commercialisation. In this second group, which are essential is within choose secoles. <b>Support Hamman Carlos A Support Hamman C</b>	vo categories. The first group are stocks with existing positive cash flows ea		early stages commercialisation.
<pre>ges of commercialisation. In this second group, which are essent is well within those stocks.</pre>	thout near te	erm positive cash flows, history of losses, or at early	Speculative Buy – Class A
<pre>by speciality: propositions. <i>Bioshares</i> grades them according to itis within those stocks.</pre>	ges of comn	nercialisation. In this second group, which are essen-	These stocks will have more than one technology, product or
<pre>min charge winnin that group, to be there relies the very large spread is winnin the stroke.  presente stoke.  presentes</pre>	lly speculati	ive propositions, <i>Bioshares</i> grades them according to	investment in development, with perhaps those same technologies
<pre>indicate the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation of the stack is relative less risky than other bioach stacks. Supplementation is stack by the stack is relative less risky than other bioach stacks. Supplementation is stack by the stack is relative less risk other is stack by the less relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative less risk other is stack by the stack is relative les</pre>	ative risk wi	thin that group, to better reflect the very large spread	presence of alliances, partnerships and scientific advisory boards,
Specialitie Bay - Class B         Specialitie Bay - Class C         The Special	iisk within		indicate the stock is relative less risky than other biotech stocks.
<pre>det with existing positive cash flows or close to producing positive cash set. y</pre>	oup A		Speculative Buy – Class B
<pre>series de grand key areas. For example, their cash position is weak, or management or board may need strengthening: Yeah er CMP in CMP is 10% s Fair Value Weine CMP is 10% s Fair Value CMP is 20% s Fair Value CMP is 2</pre>	cks with exis	sting positive cash flows or close to producing positive cash	may even be close to market. However, they are likely to be lacking in
y         CMP is 20% <fair td="" value<="">         management or board may need strengthening.           bit         Value = CMP         management or board may need strengthening.           bit         Value = CMP         Speculative Buy - Class C           CMP is 20% &gt; Fair Value         The set stocks generally have one product in development and lack may external validation features.           Speculative Hold - Class A or B or C         Speculative Hold - Class A or B or C           Set         Speculative Hold - Class A or B or C           Speculative Hold - Class A or B or C         Speculative Hold - Class A or B or C           chem Carbon Hormanecuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen armaccuticals, Peplin, BioMD           science         Set           ormation contained in this sevideter in on a complete subject to change, Biale halary and Makar Analyset PJ Laf (BAA) and any of the avaerate, officer on staff any have one produced breat should make than any three may any intermation of publicities and are bayes to change, Biale halary and Makar Analyset PJ Laf (BAA) and any of the avaerate, officer on staff any have one and publication of this report is second to or second any of the avaerate, officer on staff any have one any other avaerate avaerate (Corporations Law 4.851). The pronoit is over anterial for the peptiane and publication of this report is the change BAA Nather and avaerate avaerate (Corporations Law 4.851). The pronoit is over anterial for the peptiane and publication of this report is development and publication of this report is development avaerate avaerate avaerate avaerate avaerate ava</fair>	ws.		several key areas. For example, their cash position is weak, or
cmmutar       CMP is 10% < Fart Value	ıy	CMP is 20% < Fair Value	management or board may need strengthening.
min       CMB       Value       many external validation features:         min       CMP is 20% > Fair Value       Speculative Hold - Class A or B or C         Synchronic Hold - Class A or B or C       Soft         ProTatel Subscribers:       Phylogica, Neuren Pharmaceuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen armaceuticals, Peplin, BioMD         column       Content Market Price         column       Content Analysis Ppl (al. MBA)         column       Content Market Price         column       Content Analysis Ppl (al. MBA)         column       Content Analysis Ppl (al. MBA)      <	cumulate	CMP is 10% < Fair Value	Speculative Buy – Class C These stocks generally have one product in development and lack
Image: CMP is 2008. > Fair Value       Speculative Hold - Class A or B or C         MP-Current Market Price)       Sell         Sell       Speculative Hold - Class A or B or C         Sell       Speculative Hold - Class A or B or C         Sell       Speculative Hold - Class A or B or C         Sell       Speculative Hold - Class A or B or C         Speculative Hold - Class A or B or C       Speculative Hold - Class A or B or C         Speculative Hold - Class A or B or C       Specific A Biolicen, Peptich, Biodel         ChemeGenex Pharmaceuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen armaceuticals, Peplin, BioMD       Stem Cell Sciences, Haleygen armaceuticals, Peplin, BioMD         schian:       Specific A Issue (Specific A Issue) (Sp	ghten	CMP is 10% > Fair Value	many external validation features.
MP-Current Market Price)     Sell       Opported & Subscribers:     Phylogica, Neuren Pharmacuiculas, Pharmaxis, NeuroDiscovery, Prima Biomed, Biotech Capital, genics, Cytopia, Biodiem, Peptech, Starpharma Holdings, Cogstate, Xeeed Biotechnology. Incitive, Optiscan Imaging, Bionor, ChemGenex Pharmaceuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen armaceuticals, Peplin, BioMD       schamaceuticals, Peplin, BioMD       schamaceuticals, Copromotion, Law, Science State, Neuroscience, Tialis Industry and Market Analysis Pt J 4d (BMA) and any of there expenses or staff may bare scheme, Organization and particular neets. Accordingly, on respective for general circulation and do not have exait to scheme scheme and variance that and particular neets. Accordingly, on respective for general on any persons or imprive the information hereit is secarate but no warmty of accuracy is given and persons seeking to ety on information providel beere spress or impleiodic contained in secarate but no warmty of accuracy is given and persons seeking to ety on information providel beere spress or impleiodic contained in the according the an environmentation (Accesses). The possing information providel beere spress or independent on these the stage of the present in securities but no warmty of accuracy is given and persons seeking to ety on information providel beere interasts and not house they accel for the present on additional securities and additional securities and additional scheme spress of market and additional environmentation of the present on testic interastic and person company industry in water base persons or material additional environmentation (Accesses) in accesses are change at any time and are oradification metal additional environmentation (Accesses).       Subscription Category of the present person of mareting person of additinal person of addit	11	CMP is 20% > Fair Value	Speculative Hold – Class A or B or C
Sponde Subscribers: Phylogica, Neuren Pharmaceuticals, Pharmaxis, NeuroDiscovery, Prima Biomed, Biotech Capital, Bionor, ChemGenex Pharmaceuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen armaceuticals, Peplin, BioMD science: Tomation contained in this newsthere is not a complete analysis of every material fact repeting any company, industry or security. The ophions and estimates berein expressed meres the sciences to change, Bida Holdings, no recipients and values to the securities regressed islaudian adparticular needs. AccA Mayles PtJ Ld (MNA) and any of thera associas, officers or astim any bave merest in scentities referred to heavin (Corporation Law s480). Datalic contained herein have been prepared for general circulation (whether capress of mighlo) contained in a decimate baren bare base and particular each. AccCA MAND, and any of thera associas, officers or astim advector decimates bare in advectory of capronalis, no recipients on a decimate baren bare bare and particular each. AccCA MAND, and any of thera associas, officers or astim advectory of capronalis on the base frequent on advectory of accurscipt signe and persons secting: ACL, ACR, NDA, MIS, NOS, NTA, COS, CYC, SN, IXA, TM, OHL, PND, PSS, SNC, SPL, SNT, TISUBI. These interests can change at any time and are not additional recommendations. Holdings in socks valued at a than 3100 are not disclored for \$\$\$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge may credit card \$\$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge may credit card \$\$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$\$ MasterCard \$\$ MasterCard \$\$ value \$\$\$ made payable to Blake Industry deta metal addresses Tricing structure is as follows: \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$ \$\$	MP-Current	t Market Price)	Sell
<pre>genues, cy.uopa, Booden, replech, Starpaarna Hoddings, Cogstate, Accede Brobechnology, Inclusive, Optiscan Imaging, Biond charactericals, Peplin, BioMD</pre>	orporate	<b>SUDSCRIDERS:</b> Phylogica, Neuren Pharmaceuti	cals, Pharmaxis, NeuroDiscovery, Prima Biomed, Biotech Capital,
<pre>structure is negative to the properties of the properties of</pre>	genics, Cy	nopia, Biodiem, Peptecn, Starpharma Holdings, C	ugstate, Acceu Biotechnology, Incitive, Optiscan Imaging, Bionom
exhimin: Grading on the second sec	armaceutic	cals. Peplin. BioMD	r reemologies, blota nordings, stem een selences, naieygen
Subscription Rates (inc. GST)         48 issues per year (electronic distribution): \$320         For subscription email distributions within \$550       2-3 email addresses         pricing structure is as follows:       \$950       4-5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         To subscript, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9671 3633         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	nterests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person's or ompany's investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in his document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report elieve the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent nquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: ACL, ACR, BDM, BLS, BOS, BTA, CGS, CYT, CXS, HXL, .CT, MBP, OIL, PAB, PEP, PGL, PTD, PXS, SHC, SPL, SLT, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at ess than \$100 are not disclosed.		
For multiple email distributions within \$550       2-3 email addresses the same business cost centre, our \$750       4-5 email addresses pricing structure is as follows: \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9671 3633         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number        Expiry date         Signature	Subscription Rates (inc. GST) 48 issues per year (electronic distribution): \$320		
It is same ubsiness cost centle, out       \$150       4-5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         Structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares       PO Box 193 Richmond VIC 3121         Fax: 61 3 9671 3633       I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	For multiple email distributions within \$550 2-3 email addresses		
To subscribe, post/fax this subscription form to:       Bioshares D Box 193 Richmond VIC 3121 Eax: 61 3 9671 3633         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard         Card Number          Signature       Expiry date         Subscriber details         Name	the same business cost centre, our \$750 4-5 email addresses pricing structure is as follows: \$950 6.10 email addresses		
To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9671 3633 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa			
PO Box 193 Richmond VIC 3121         Fax: 61 3 9671 3633         I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$ MasterCard   Visa           Card Number	To sub	oscribe, post/fax this subscription form to:	Bioshares
Fax: 61 3 9671 3633         I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$ MasterCard Visa         Card Number			PO Box 193 Richmond VIC 3121
I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or   Please charge my credit card \$ MasterCard   Visa			Fax: 61 3 9671 3633
Please charge my credit card \$ MasterCard Visa   Card Number   Signature   Subscriber details   Name   Organisation   Ph ( )   Emails	I enclo	ose a cheque for \$ made payable to	D Blake Industry & Market Analysis Pty Ltd, or
Card Number	Please charge my credit card \$ MasterCard Visa		
Signature	Card N	Number	
Signature          Subscriber details	Calu		
Subscriber details         Name	Signat	Signature Expiry date	
Name   Organisation   Ph ( )   Emails	Subscriber details		
Organisation Ph ( ) Emails	Name		
Ph ( ) Emails	Organ	isation	
Emails	Ph (	)	
	Emails	5	